Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule
12 November 2019 - 12:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) therapies for cancer, today announced that
management plans to present at two media events through the end of
the year.
David Chang, M.D., Ph.D., President, Chief Executive Officer and
Co-Founder of Allogene will participate in a panel fireside chat at
the Atlantic’s People v. Cancer event called “Can Immunotherapy
Scale Up?” on November 12, 2019. Arie Belldegrun, M.D., FACS,
Executive Chairman and Co-Founder of Allogene will present during
the lunchtime keynote at the Cell Therapy & the Potential
to Revolutionize the Future of Cancer Treatment on November 21,
2019 on “Cell Therapy & the Potential to Revolutionize the
Future of Cancer Treatment”. Neither presentation will be
webcast.
The Atlantic’s People v. CancerFireside Chat November 12,
2019New York, NY
Cell Therapy & the Potential to Revolutionize the Future of
Cancer TreatmentLunch KeynoteNovember 21, 2019Boston, MA
Allogene Therapeutics will also be presenting at three investor
conferences through the end of the year. The investor presentations
will be webcast and made available on the Company's website
at www.allogene.com under the Investors tab in the News and
Events section. Following the live audio webcast, a replay will be
available on the Company's website for approximately 30 days.
Stifel 2019 Healthcare ConferenceTuesday, November 19, 2019 at
11:25 AM PT/2:25 PM ETNew York City, NY
Jefferies 2019 London Healthcare ConferenceNovember 20, 2019 at
12:40 AM PT/3:40 AM ETLondon, England
Piper Jaffray 31st Annual Healthcare ConferenceDecember 4, 2019
at 6:00 AM PT/9:00 AM ETNew York City, NY
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the
development of allogeneic chimeric antigen receptor T cell
(AlloCAR T™) therapies for cancer. Led by a world-class management
team with significant experience in cell therapy, Allogene is
developing a pipeline of “off-the-shelf” CAR T cell
therapy candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and
at greater scale to more patients. For more information,
please visit www.allogene.com, and follow @AllogeneTx on
Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for
AllogeneThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should" or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the ability to develop allogeneic
CAR T therapies for cancer and the potential benefits of AlloCAR T
therapy. Various factors may cause differences between Allogene’s
expectations and actual results as discussed in greater detail in
Allogene’s filings with the Securities and Exchange Commission
(SEC), including without limitation in its Form 10-Q for the
quarter ended September 30, 2019. Any forward-looking
statements that are made in this press release speak only as of the
date of this press release. Allogene assumes no obligation to
update the forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Apr 2024 to May 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From May 2023 to May 2024